This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis
by Zacks Equity Research
The biotech sector was in the news last week as shares of Spectrum surged on positive data from a phase II study while Incyte plunged on the failure of melanoma study.
Agios Pharmaceuticals Shares Rise on Buyout Speculation
by Zacks Equity Research
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
Company News For Apr 10, 2018
by Zacks Equity Research
Companies in the news are: PME,CBS,WATT,AVXS,NVS
Novartis and Other Drug Stocks With FDA Catalysts in April
by Kinjel Shah
With just a quarter gone by this year, the FDA has already granted approval to six new treatments.
Novartis Inks $8.7 Billion Gene Therapy Deal to Buy AveXis
by Zacks Equity Research
Novartis (NVS) signs a contract to purhcase the U.S. based clinical stage gene therapy company, AveXis, Inc for a cash-tender offer of $218 per share.
Sonoma Up on FDA Approval of Antimicrobial Post-Therapy Gel
by Zacks Equity Research
Sonoma's (SNOA) shares gain after the FDA approves its antimicrobial post-therapy gel for the management of post-non-ablative laser therapy procedures.
Novartis Announces Data on Cardiovascular Drug Entresto
by Zacks Equity Research
Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.
Conatus' Emricasan Fails in Phase II Study, Shares Sink
by Zacks Equity Research
Conatus Pharmaceuticals' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on liver transplant patients with fibrosis or cirrhosis.
GlaxoSmithKline's Horlicks Up for Grabs: Who Will Snap It Up?
by Zacks Equity Research
As GlaxoSmithKline (GSK) starts a strategic review of Horlicks and other smaller nutrition products, a number of companies in the food & beverage industry are waiting to scoop it up.
Rigel (RIGL) Sinks on Failure of Mid-Stage Study on Lead Drug
by Zacks Equity Research
Rigel's (RIGL) stock plunges 13% on the failure of a phase II study on lead drug, fostamatinib, in patients with IgA nephropathy (IgAN).
Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale
by Zacks Equity Research
Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.
Amgen's (AMGN) Xgeva Gets EU Approval for Expanded Label
by Zacks Equity Research
Amgen (AMGN) gets EU approval to expand the label of its key drug, Xgeva to include patients with multiple myeloma.
Puma's Shares Fall This Year Post a Solid 2017: Here's Why
by Zacks Equity Research
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Shire's Stock Continues to Rise as Takeda Sets Eyes On it
by Zacks Equity Research
Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.
Company News For Mar 28, 2018
by Zacks Equity Research
Companies in the news are: RHT,MKC,INFO,GSK,NVS
Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV
by Zacks Equity Research
Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.
Merck, Eisai Get Japanese Nod for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and partner Eisai receive approval in Japan for Lenvima for the first line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Novartis Gets Positive CHMP Opinion on Biosimilar Remicade
by Zacks Equity Research
The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.
Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus
by Zacks Equity Research
Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.
4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18
by Zacks Equity Research
Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.
Roche's (RHHBY) Lucentis 0.3 mg PFS Receives FDA Approval
by Zacks Equity Research
Roche's (RHHBY) opthalmology drug, Lucentis 0.3 mg prefilled syringe (PFS) is a new method of administering medicine for all forms of diabetic retinopathy.
Regeneron Eylea Hits 24-Week Primary Endpoint in Study
by Zacks Equity Research
Regeneron (REGN) announces encouraging top-line results from the phase III study evaluating Eylea injection in moderately severe to severe non-proliferative diabetic retinopathy.
Is Novartis (NVS) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene
Why Multiple Sclerosis is a Promising but Risky Space?
by Zacks Equity Research
Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.